pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

3,133 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1185Endpoints904BioPharma Dive348BioSpace321Fierce Biotech302onclive165raps107globenewswire health
therapy area
allOncology7795Rare Disease1893Cardiology1782Immunology1514Hematology1329Vaccines1208Pulmonology
  • FDA authorizes fruit-flavored vapes amid political pressure, sparking debate over youth risk and quitting aid
    The U.S. Food and Drug Administration granted its first authorization for fruit-flavored e-cigarettes on Tuesday, adding mango- and blueberry-tasting products from Los Angeles-based Glas to its app…
    STAT · 4mo agoRegulatoryNeutral↗ source
  • Madrigal's Rezdiffra sales top forecasts as Gilead announces job cuts
    Madrigal Pharmaceuticals reported first‑quarter sales of its MASH drug Rezdiffra at $311 million, roughly $10 million above analyst expectations, according to TD Cowen. The outperformance highligh…
    Endpoints · 4mo agoEarningsNeutral↗ source
← prev
page 115 of 126
next →
73
fda recalls70
fda medwatch60
fda press38
1203
Psychiatry & CNS870
Ophthalmology508
Pain483
Endocrinology & Metabolism483
Infectious Disease450
  • Former Orbital scientists launch ParcelBio with $13 million seed round to boost mRNA therapy durability
    Two former Orbital Therapeutics scientists, Chris Carlson and David Weinberg, have founded a new company called ParcelBio. The startup aims to address a technical limitation that has hindered the…
    Endpoints · 4mo agoDealPositive↗ source
  • PhRMA launches seven-figure ad campaign against 340B drug discount program
    PhRMA, the leading pharmaceutical lobbying group, announced a new advertising push aimed at the federal 340B drug discount program. The campaign, described as a seven-figure effort, is set to begi…
    STAT · 4mo agoRegulatoryNeutral↗ source
  • BeOne Medicines trims five cancer programs and an autoimmune Phase 2 candidate
    BeOne Medicines has significantly broadened its research portfolio, adding 18 new molecular entities slated for development in 2024 and 2025. Despite the expansion, the company announced it will d…
    Endpoints · 4mo agoNegative↗ source
  • STAT+: How a global effort to explore the ‘dark proteome’ is upending our understanding of human disease
    An international team has found thousands of mini-proteins, including some involved in cell division and DNA repair, as well as several unique to cancer cells.
    STAT · 4mo agoRegulatoryNeutral↗ source
  • Health AI progress limited by bad data, newsletter notes
    The latest AI Prognosis newsletter highlights that the quality of health data is a major obstacle for building useful AI tools in medicine. The author explains that many existing datasets contain…
    STAT · 4mo agoNeutral↗ source
  • HHS focuses on overmedication as cruise ship hantavirus outbreak prompts port change
    The Health and Human Services department announced new efforts to curb excessive prescribing, highlighting concerns about overmedication in the United States. At the same time, a cruise ship ancho…
    STAT · 4mo agoNeutral↗ source
  • OpenAI’s health AI policy blueprint seen as reasonable yet self‑serving, experts say
    OpenAI has expanded its health‑focused AI tools, rolling out ChatGPT Health for consumers, a hospital‑oriented ChatGPT for Healthcare, and a version for clinicians. Alongside the clinician chatbot,…
    STAT · 4mo agoRegulatoryNegative↗ source
  • PeaceHealth abandons plan to outsource Oregon emergency doctors to ApolloMD after lawsuit and local opposition
    PeaceHealth, a nonprofit health system in Oregon, announced Wednesday that it will not move its emergency department staffing to the national physician staffing firm ApolloMD. The decision reverse…
    STAT · 4mo agoRegulatoryNeutral↗ source
  • Dementia care faces ambiguous loss, a unique grief that strains relationships
    Jason Karlawish, a professor of medicine and neurology at the University of Pennsylvania, wrote an opinion piece on the concept of ambiguous loss in dementia care. He reflects on a recent interview…
    STAT · 4mo agoNeutral↗ source
  • Dr. Glaucomflecken protests corporate staffing of PeaceHealth emergency department in Oregon
    Dr. Glaucomflecken, the online persona of physician Will Flanary, hosts the First Opinion Podcast where he blends humor with health‑care commentary. He has become a vocal critic of PeaceHealth’s p…
    STAT · 4mo agoNegative↗ source
  • STAT+ examines AI diagnostic claims, telehealth abortion access and Epic lawsuit in latest health tech newsletter
    STAT+ published a health‑tech newsletter that asks whether artificial intelligence has truly outperformed physicians in diagnosing disease, citing a high‑profile study on AI diagnostic performance.…
    STAT · 4mo agoNeutral↗ source
  • Intercept's next-gen FXR agonist fails Phase 2 in latest setback for Italian-owned pharma
    Intercept Pharmaceuticals' attempt at creating a next-generation FXR agonist for certain forms of liver inflammation appears to have ended. The drug developer's INT-787 showed "no clear evidence of…
    Endpoints · 4mo ago↗ source
  • Pfizer's Albert Bourla says he has no mega-merger plans
    The most candid man in pharma strikes again. When asked on Tuesday’s earnings call whether Pfizer would consider a “transformative M&A” deal in the near or medium term, CEO Albert Bourla said it wo…
    Endpoints · 4mo ago↗ source
  • STAT+: Pharma’s reputation among patient groups rose last year, but concerns remain over access and pricing
    The pharma industry saw its reputation among patient groups inch up last year, a new survey finds, but concerns remain over access and pricing.
    STAT · 4mo ago↗ source
  • STAT+: A new attack on AMA’s billing codes
    A key GOP lawmaker is broadening the party's efforts to combat health care fraud.
    STAT · 4mo ago↗ source
  • BioNTech to scale down manufacturing, over 1,800 jobs on the line
    BioNTech is making big cuts to its manufacturing footprint. The German company said in its first-quarter earnings release that up to 1,860 manufacturing staff could be impacted by its planned downs…
    Endpoints · 4mo ago↗ source
  • Parsley Health goes in-network nationwide
    When I first heard about Parsley Health close to a decade ago, the startup embodied a few trends I was following closely: primary care startups and cash-pay healthcare. For a ...
    Endpoints · 4mo ago↗ source
  • Viridian data lift prospects for thyroid eye disease drug
    Whereas earlier Phase 3 results disappointed Wall Street, new findings in people with “chronic” disease were viewed by analysts as much more competitive with Amgen’s Tepezza.
    BioPharma Dive · 4mo ago↗ source
  • Second life for gene therapy; Takeda Phase 2/3 win; UK cancer biotech's $83M
    A blood test might predict who will respond to Wegovy; Viridian's thyroid eye disease drug wins another Phase 3; Ideaya drops two GSK-returned assets. 🧬 Second life for a gene therapy: A Cleveland…
    Endpoints · 4mo ago↗ source
  • Swiss manufacturing, biotech industry so far unfazed by geopolitics
    BASEL, Switzerland — Pharma manufacturing in Switzerland appears to be unperturbed by the threat of tariffs, but it might take several years before the impact of companies moving production to the…
    Endpoints · 4mo ago↗ source
  • Pfizer ends Trillium-related development as R&D spend jumps
    Pfizer has discontinued the final clinical study stemming from its 2021 acquisition of Trillium Therapeutics, funneling cash primarily toward a host of other cancer and obesity studies. The company…
    Endpoints · 4mo ago↗ source
  • STAT+: Are analysts too quick to gloss over Lilly’s liver case?
    Cytokinetics' Myqorzo's trial results, Johnson & Johnson's IBD therapy, and more biotech news from The Readout
    STAT · 4mo ago↗ source
  • Microbiome startup raises $48M for immunotherapy and malnutrition treatments
    Scientists trying to understand why cancer immunotherapy works so well for some patients and not others have found a potential answer in one cancer survivor's poop. A biotech startup has studied th…
    Endpoints · 4mo ago↗ source